pdufa.bio
Home › Decisions › BIIB 2026-03-30

BIIB FDA decision — Mar 30, 2026

✓ APPROVED

Biogen Inc. — SPINRAZA (Nusinersen) - (DEVOTE) · Spinal muscular atrophy (SMA).

Run-up into the decision (T-120 → T+5)

PDUFA 3/30/26$201.18$142.2610/13/25
Daily close, T-120 (10/13/25) through T+5. Run-up high $201.18 on 2/9/26, low $142.26 on 10/23/25 (T-120 to T-1). FDA decision 3/30/26. Historical price action, not a forecast.

Key facts

FDA decision date2026-03-30
OutcomeApproved
Drug / candidateSPINRAZA (Nusinersen) - (DEVOTE)
CompanyBiogen Inc.
120-day run-up (T-120→T-1)+19.3%
Not affiliated with or endorsed by the FDA. Informational and educational only — not investment advice. Verify against primary FDA / SEC / company filings. © 2026 pdufa.bio